Infant formula containing galacto-and fructo-oligosaccharides and Bifidobacterium breve M-16V supports adequate growth and tolerance in healthy infants in a randomised, controlled, double-blind, prospective, multicentre study

• Published in: Journal of nutritional science (Cambridge) Vol. 5; p. e42
• Main Authors: Abrahamse-Berkeveld, M., Alles, M., Franke-Beckmann, E., Helm, K., Knecht, R., Köllges, R., Sandner, B., Knol, J., Ben Amor, K., Bufe, A.
• Format: Journal Article
• Language: English
• Published: Cambridge, UK Cambridge University Press 2016
• Subjects: Age; Allergies; anthropometric measurements; Antibiotics; Asthma; Babies; Baby foods; Bifidobacterium breve; Bifidobacterium breve M-16V; Birth weight; blood composition; Breastfeeding & lactation; Clostridium histolyticum; Clostridium lituseburense; Congenital diseases; Dermatitis; Double-blind studies; Eczema; Families & family life; Family medical history; fructooligosaccharides; galactooligosaccharides; Hydrolysed formula; hydrolysis; Immune system; infant formulas; Infant growth; infants; liver; microorganisms; Nutrition; Pediatrics; Prebiotics; Probiotics; Randomised controlled trials; renal function; Studies; Synbiotics; weight gain; Within-subjects design; World Health Organization; Netherlands; Germany; Bifidobacterium breve M-16V; Infant growth; Hydrolysed formula; Randomised controlled trials; Synbiotics; ITT, intention-to-treat; RMMM, repeated-measures mixed model; SCORAD, SCORing Atopic Dermatitis; PP, per-protocol; scGOS/lcFOS, short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides
• ISSN: 2048-6790; 2048-6790
• DOI: 10.1017/jns.2016.35

The objective of the present study was to evaluate the growth and tolerance in healthy, term infants consuming a synbiotic formula with daily weight gain as the primary outcome. In a randomised, controlled, double-blind, multicentre, intervention study infants were assigned to an extensively hydrolysed formula containing a specific combination of Bifidobacterium breve M-16V and a prebiotic mixture (short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides in a 9:1 ratio; scGOS/lcFOS; synbiotic group), or the same formula without this synbiotic concept for 13 weeks (control group). Anthropometry, formula intake, tolerance, stool characteristics, blood parameters, faecal microbiota and metabolic faecal profile were assessed. Medically confirmed adverse events were recorded throughout the study. Equivalence in daily weight gain was demonstrated for the intention-to-treat (ITT) population (n 211). In the per-protocol (PP) population (n 102), the 90 % CI of the difference in daily weight gain slightly crossed the lower equivalence margin. During the intervention period, the mean weight-for-age and length-for-age values were close to the median of the WHO growth standards in both groups, indicating adequate growth. The number of adverse events was not different between both groups. No relevant differences were observed in blood parameters indicative for liver and renal function. At 13 weeks, an increased percentage of faecal bifidobacteria (60 v. 48 %) and a reduced percentage of Clostridium lituseburense/C. histolyticum (0·2 v. 2·6 %) were observed in the synbiotic group (n 19) compared with the control group (n 27). In conclusion, this study demonstrates that an extensively hydrolysed formula with B. breve M-16V and the prebiotic mixture scGOS/lcFOS (9:1) supports an adequate infant growth.